Condition: Breast Cancer · Breast Cancer Female · Metastatic Triple-Negative Breast Carcinoma · Sponsor: Sarah Sammons, MD
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
This description comes directly from the study's public registry record.
Sarah Sammons, MD · 617-362-3800 · sarahl_sammons@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Miami Baptist Cancer Institute/ | Miami, Florida, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06176261